SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

Search

Innate Pharma SA

Open

1.824 1.11

Overview

Share price change

24h

Current

Min

1.7

Max

1.856

Key metrics

By Trading Economics

Income

-25M

Sales

12M

Profit margin

-200.599

Employees

181

EBITDA

-26M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+143.09% upside

Market Stats

By TradingEconomics

Market Cap

159M

Previous open

0.71

Previous close

1.824

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Innate Pharma SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2025, 23:55 UTC

Hot Stocks

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 kwi 2025, 22:50 UTC

Major Market Movers

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 kwi 2025, 21:08 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 kwi 2025, 21:00 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 kwi 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 kwi 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 kwi 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 kwi 2025, 23:44 UTC

Top News

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 kwi 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 kwi 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 kwi 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 kwi 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 kwi 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 kwi 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 kwi 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 kwi 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 kwi 2025, 22:43 UTC

Top News
Acquisitions, Mergers, Takeovers

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 kwi 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 kwi 2025, 21:48 UTC

Top News

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 kwi 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 kwi 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 kwi 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 kwi 2025, 21:04 UTC

Top News

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 kwi 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 kwi 2025, 20:53 UTC

Earnings

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 kwi 2025, 20:52 UTC

Earnings

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer Comparison

Price change

Innate Pharma SA Forecast

Price Target

By TipRanks

143.09% upside

12 Months Forecast

Average 4.4 EUR  143.09%

High 5.7 EUR

Low 3.1 EUR

Based on 2 Wall Street analysts offering 12 month price targets forInnate Pharma SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

1.836 / 1.88Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.